EUVIMEDEUVIMED entdecken
Beobachtungsstudie

In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness

Nicolas Bourgon iD, Remi Lopez, Jacques Fourgeaud iD, Tiffany Guilleminot, Laurence Bussières, Jean-François Magny, Yves Ville, Marianne Leruez Ville

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae247 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Nicolas Bourgon und 7 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Fetal Medicine Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Valganciclovir, Cytomegalovirus Infections, Antiviral Agents, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The treatment of congenital cytomegalovirus (CMV) infection is usually administered to neonates after birth; however, it can be anticipated during the prenatal period by treating pregnant women in order to reduce the severity of the congenital disease. The most commonly used treatment for CMV during pregnancy is valaciclovir; however, valganciclovir has a higher potency against CMV and is the first choice for neonates with congenital CMV disease.

Objectives

We investigated neonatal and maternal safety of tertiary prevention in infected fetuses showing ultrasound features of infection using valganciclovir.

Methods

Retrospective cohort study of pregnant women and their symptomatic infected fetuses taking valganciclovir, 3 × 450 mg per day. All fetuses presented at least one prenatal feature on ultrasound. We assessed fetal/neonatal and maternal safety, as well as neonatal efficacy of treatment. The main outcome was neutropenia. Secondary outcomes included other haematological side effects, symptoms at birth and neonatal CMV-PCR was positive.

Results

Seventeen women with singleton pregnancies received valganciclovir from a median (IQR) of 27.1 (26.0–30.3) to 11.6 (6.5–12.9) weeks of gestation. No neonatal neutropenia was reported. One pregnancy was terminated for severe features. Three newborns (18%) were asymptomatic at birth, including one with negative CMV-PCR from blood and saliva. CMV-PCR was positive for 12/13 symptomatic newborns, with a median (IQR) log10 viral load of 3.36 (3.30–4.20), 4.03 (1.75–4.27) and 3.04 (0.00–3.40) log10 copies/mL in blood, urine and saliva, respectively.

Conclusions

Tertiary prevention by valganciclovir appears to be well tolerated for both fetus and mother. However, more extensive trials accompanied by long-term follow-up are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValganciclovirCytomegalovirus InfectionsAntiviral AgentsPregnancy Complications, InfectiousHumansFemalePregnancyRetrospective StudiesInfant, NewbornAdultTreatment OutcomeCytomegalovirusGanciclovirInfectious Disease Transmission, Vertical

Substanzen

ValganciclovirAntiviral AgentsGanciclovir

Autor:innen und Institutionen

  • Obstetrics and Fetal Medicine Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.
  • INSERM UMR-1163, Institut Imagine, Université Paris Cité, Paris, France.
  • Virology Laboratory-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.
  • URP « FŒTUS » 73-28, Université Paris Cité, Paris, France.
  • Neonatal Medicine and Intensive Care Unit-Hôpital Necker Enfants Malades, GHU Paris Centre, AP-HP, Paris, France.

ORCID-Profile: Nicolas Bourgon, Jacques Fourgeaud

Zitieren

APA

Bourgon, N., Lopez, R., Fourgeaud, J., Guilleminot, T., Bussières, L., Magny, J. F., Ville, Y., & Leruez Ville, M. (2024). In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae247

Vancouver

Bourgon N, Lopez R, Fourgeaud J, Guilleminot T, Bussières L, Magny JF, et al. In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae247

BibTeX
@article{Bourgon2024,
  author = {Bourgon, Nicolas and Lopez, Remi and Fourgeaud, Jacques and Guilleminot, Tiffany and Bussières, Laurence and Magny, Jean-François and Ville, Yves and Leruez Ville, Marianne},
  title = {In utero treatment of congenital cytomegalovirus infection with valganciclovir: an observational study on safety and effectiveness},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae247}
}
Kostenlos starten →